Insmed soars as blood pressure drug succeeds in mid-stage trial

Shares of drugmaker Insmed INSM.O rise 24.9% to $88.28 premarket

Co says its treprostinil palmitil inhalation powder (TPIP) met the main goal in a mid-stage trial by reducing blood flow resistance in the lungs by 35% when compared to placebo

The drug was tested in patients with Pulmonary Arterial Hypertension (PAH), a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure

Co says the treatment is administered once-daily in a capsule-based inhalation device

INSM says it plans to initiate a late-stage trial for the drug in early 2026

Up to last close, stock up 2.4% YTD